Drug Trial Radar · NCT06700343
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
152
Actual
Start
Jan 13, 2025
Primary completion
Apr 19, 2027
Study completion Oct 4, 2027
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
Ocrelizumab (US)Drug
IV infusion
Ocrelizumab (EU)Drug
IV infusion
ABP 692Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)Time frame: Day 1 to Day 15
- AUC From Time 0 Extrapolated toInfinity (AUC0-inf) of the Entire Initial Dose of IPTime frame: Day 1 to Week 16
Locations
109 sites in 22 countries. Site status is shown where the registry gives one.
University of South Alabama
Mobile, Alabama
Clinical Endpoints, LLC
Scottsdale, Arizona
Profound Research - Neurology Center of Southern California
Carlsbad, California
Mountain Neurological Research Center
Basalt, Colorado
Advanced Neurosciences Research, Llc
Fort Collins, Colorado
Hasbani Neurology
New Haven, Connecticut
Neurology Offices of South Florida
Boca Raton, Florida
Aqualane Clinical Research
Naples, Florida
Emerald Coast Neurology/Synergy Clinical Research
Pensacola, Florida
Knight Neurology
Rockledge, Florida
Premiere Research Institute Palm Beach
West Palm Beach, Florida
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Rush University Medical Center, Rush University Cancer Center
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Henry Ford Health
Detroit, Michigan
Michigan Institute For Neurological Disorders (Glendale Neurological Associates) - Farmington Hills
Farmington, Michigan
JFK Medical Center
Edison, New Jersey
Hackensack Meridian Health
Paramus, New Jersey
University of NM/Mind Imaging center
Albuquerque, New Mexico
Triad Neurological Associates
Winston-Salem, North Carolina
Singlepoint Healthcare Opco, LLC
Columbus, Ohio
NDx Clinical Research, Inc
Dayton, Ohio
Premier Neurology, PC
Greenville, South Carolina
Hope Neurology
Knoxville, Tennessee
Vanderbilt University Medical Center (VUMC)
Nashville, Tennessee
Lone Star Neurology
Frisco, Texas
Froedtert Hospital-Medical College of Wisconsin
Milwaukee, Wisconsin
MS-Netwerk Limburg - Revalidatie & MS Centrum
Overpelt, Belgium
Algemeen Ziekenhuis Delta
Roeselare, West-Vlaanderen, Belgium
UMHAT Dr.Georgi Stranski EAD
Pleven, Bulgaria
University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski
Sofia, Bulgaria
Medical Center Hera EOOD
Sofia, Bulgaria
UMHATEM N.I. Pirogov
Sofia, Bulgaria
Diagnostic Consultative Center Convex Ltd
Sofia, Sofiiska, Bulgaria
Foothills Medical Centre
Calgary, Alberta, Canada
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Sestre milosrdnice University Hospital Center
Zagreb, Croatia
University Hospital Centre Zagreb
Zagreb, Croatia
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Fakultni Nemocnice Hradec Kralove
Hradec Králové, Czechia
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.